Precision Clinical Pharmacology
Preliminary program
Saturday 8 June 2024
-
09:00 - 18:30Willem Burger HalRegistration
-
10:00 - 12:00Zaal 1Seminar: ‘How to pick the right dose: Basic concepts of using PBPK modeling in special populations’
-
10:00 - 10:10Welcome
-
10:10 - 10:40LE 1: PK changes in paediatric and pregnancy
-
10:40 - 11:10LE 2: Basic concepts of PBPK modelling + demo
-
11:10 - 11:30Short break to stretch legs
-
11:30 - 12:00LE 3: PBPK in special populations
-
-
12:00 - 13:00Willem Burger FoyerLunch (included)
-
13:00 - 16:00Zaal 4Workshop: ‘How to pick the right dose: Hands-on experience with PBPK modelling in special populations’ (PRE-REGISTERED)
-
13:00 - 13:15Create groups, start software, resolve technical issues
-
13:15 - 14:00Hands-on A: Paediatric PBPK modelling
-
14:00 - 14:20Hands-on A: Plenary discussion
-
14:20 - 14:30Coffee break
-
14:30 - 15:15Hands-on B: Pregnancy PBPK modelling
-
15:15 - 15:35Hands-on B: Plenary discussion
-
15:35 - 15:45Wrap up
-
-
13:00 - 16:30Zaal 1Pre-meeting clinical pharmacologists in training and early career
-
13:00 - 13:45Toxicology from Rotterdam, the biggest harbour in Europe
-
13:45 - 14:15Update EACPT early career survey
-
14:15 - 14:45Planetary health in education in prescribing Joost Piët
-
14:45 - 15:05Short break
-
15:05 - 16:30Quiz and speed dating early career clinical pharmacologists
-
-
16:30 - 18:30Willem Burger FoyerCongress Reception
Sunday 9 June 2024
-
08:00 - 14:00Willem Burger HalRegistration
-
09:00 - 10:35Zaal 1Plenary Session 1 | The WHO 6-Step concept, drug shortages, precision targeting
WHO Step: 1-6
-
09:00 - 09:15Welcome
Explanation of research agenda: advanced 6-step
-
09:15 - 09:45Drug shortages - how to tackle this multi-headed monster
-
09:45 - 10:15Precision targeting in innate immunity
-
10:15 - 10:35Zaal 1Poster Pitches
WHO Step: 1-2
Abstracts
10:15 - 10:1731 | Angiomorphometric Of Breast Carcinoma and Prognostic BiomarkersBy: MUNA DAWOOD BAWAZEER
10:17 - 10:1977 | Evaluating the Efficacy of Alpha Lipoic Acid in the Treatment of Thermal Ocular Burns: A Comparative Histopathological StudyBy: Yasemen Adalı
10:19 - 10:21119 | AZITHROMYCIN AS HOST-DIRECTED THERAPY FOR PULMONARY TUBERCULOSISBy: Bart Dekkers
10:21 - 10:23199 | Variability in Perfusion Conditions and Set-Up Parameters Used in Ex Vivo Human Placenta Models: A Literature ReviewBy: Femke Anna Elzinga
10:23 - 10:25250 | Influence of carob extract (Ceratonia siliqua L.) on metabolic disorder markers in laboratory ratsBy: Aleksandar Rašković
10:25 - 10:27257 | Effect of Epigallocatechin Gallate on Neutrophil Infiltration-Related Markers in Reperfusion InjuryBy: Furkan Toksözlü
10:27 - 10:29280 | EVALUATION OF FLUCLOXACILLIN PHARMACOKINETICS IN PEDIATRIC AND ADULT INTENSIVE CARE PATIENTSBy: Ymke Van der Velde
10:29 - 10:31309 | Salivary microbiome as a prognostic biomarker for asthma attacks in children: results from a machine-learning approach in the SysPharmPediA studyBy: Shahriyar Shahbazi Khamas
10:31 - 10:33334 | Effects of alcohol combined with energy drinks in men and women in an experimental binge drinking patternBy: Olga Hladun
10:33 - 10:35389 | The effect of dupilumab on the immunological mechanisms driving chronic rhinosinusitisBy: Patricia Jaeger
-
-
10:35 - 11:20FeestzaalCoffee Break Poster Session
Step 1. The problem
Step 2. Aim of therapy
Step 3. Therapeutic options
-
11:20 - 13:00Zaal 1Plenary Session 2 | Drug-repurposing and new therapeutic targets
-
11:20 - 11:50European network to facilitate research on Drug-repurposing and its implementation
-
11:50 - 12:20Alpha-synuclein synaptic pathology as a key therapeutic target for Parkinson's disease
-
12:20 - 13:00Lifetime achievement award winner
-
-
13:00 - 14:00FeestzaalLunch Poster Session
Step 1. The problem
Step 2. Aim of therapy
Step 3. Therapeutic options -
13:00 - 13:45Zaal 1Medbase Lunch Symposium | Decision support – Implementing drug research to clinical practice
-
13:00 - 13:30Implementing pharmacogenetic testing in clinical practice – Finnish perspective
Professor of Pharmacogenetics at University of Helsinki, Head Physician at HUS Diagnostic Center
-
13:30 - 13:40Prescribe with Precision: Decision Support for safe and effective use of drugs
Maija Kaukonen MD, PhD, A/Prof, Specialist in Clinical Pharmacology, Specialist in Anaesthesiology and Intensive Care, EDIC Medbase Ltd
-
13:40 - 13:45Discussion and questions
-
-
14:00 - 16:00Parallel Sessions 1-2-3
WHO Step: 1-2
-
14:00 - 16:00Zaal 5-8Parallel 1 | New drugable targets
-
14:00 - 14:30Secundary Mutations of TKI Targets
-
14:30 - 16:00Parallel 1 | Abstract Presentations14:30 - 14:45
By: Tomasz Bączek
14:45 - 15:00By: Alin Dumitru Ciubotaru
15:00 - 15:15By: Georgina de la Rosa Loppacher
15:15 - 15:30By: Natalia Atzemian
15:30 - 15:45By: Nadia Baalbaki
15:45 - 16:00By: Yasemen Adalı
-
-
14:00 - 16:00Zaal 9-10Parallel 2 | Brew your own
-
14:00 - 14:30Hospital exemption for ATMPs: current and future regulatory requirements
-
14:30 - 16:00Parallel 2 | Abstract Presentations14:30 - 14:45
By: Ad Roffel
14:45 - 15:00By: Dzenana Huduti
15:00 - 15:15By: Javier Queiruga-Parada
15:15 - 15:30By: Ymke Van der Velde
15:30 - 15:45By: Maha Ramadan Amin Abdollah
15:45 - 16:00By: Cedric Lau
-
-
14:00 - 16:00Zaal 1Parallel 3 | Drug-induced liver injury: from detection to prediction
Sponsored by Swiss Society of Clinical Pharmacology and Toxicology
-
14:00 - 14:30Physico-chemical characteristics of hepatotoxic drugs - and how to predict them (using machine learning)
-
14:30 - 15:00DILI: a daily challenge
-
15:00 - 15:30DILI consortium
-
15:30 - 16:00Drug-induced liver injury: present and future
-
-
-
16:00 - 16:30FeestzaalTea Break Poster Session
Step 1. The problem
Step 2. Aim of therapy
Step 3. Therapeutic options -
16:30 - 18:00Parallel Sessions 4-5
WHO Step: 1-2
-
16:30 - 18:00Zaal 1Parallel 4 | Translational Pharmacology
-
16:30 - 17:00Translational Pharmacology (winner EPHAR)
joined EPHAR and EACPT session
-
17:00 - 17:30Translational Pharmacology (winner EACPT)
-
17:30 - 18:00C14 dosimetry in ADME Studies
-
-
16:30 - 18:00Zaal 9-10Parallel 5 | Beyond small molecules
-
16:30 - 17:00RNA targeting therapies opportunities and challenges
-
17:00 - 18:00Parallel 5 | Abstract Presentations17:00 - 17:15
By: Thijs Van Iersel
17:15 - 17:30By: Aida Hadzihasanovic
17:30 - 17:45By: Henrik Huizinga
17:45 - 18:00By: Selinde Wind
-
-
-
17:00 - 19:30Satellite 1-2-3
-
17:00 - 19:30Zaal 4Satellite 1 I Education Working Group
Teach the Teacher: Workshop on the revised WHO Guide to Good Prescribing and its 6-step
-
18:00 - 19:30Zaal 1Satellite 2 I Research Working Group
-
18:00 - 18:30The basics of reproducible research practices in clinical pharmacology
-
18:30 - 19:00The concept of registered reports and their application in clinical pharmacology
-
19:00 - 19:30Brainstorm opportunities for implementation and plans for action
-
-
18:00 - 19:30Zaal 5-8Satellite 3 I Regulatory Working Group
-
18:00 - 18:20Academic challenges on advanced therapy medicinal products’ development: a regulatory perspective
Dr Elena Guillen
-
18:20 - 18:40Assessment of RNA-based therapy clinical trial applications in The Netherlands
Elias Brandorff, Jan Willem Kleinovink, Joop van Gerven (on behalf of the Dutch Central review board for research with humans, CCMO)
-
18:40 - 19:00The European Clinical Trial Regulation (ECTR) in practice: the gap between regulatory- and ethical review
-
19:00 - 19:20Panel discussion about hospital exemption and ECTR
-
-
Monday 10 June 2024
-
06:30 - 07:30Early Morning Run
On Monday 10 June, why not get your congress day off to a sportive start and join the early morning run! It’s a great way to combine a bit of sightseeing with an invigorating jog. The route takes in Rotterdam’s most iconic bridges.
Time 06.30 start depart from Erasmusbrug
Address in front of restaurant Prachtig, Willemsplein 77, 3016 DR Rotterdam
Route Erasmusbrug – Noordereiland – Willemsbrug – Maasboulevard
Bring your own water
For those who want to run from the Doelen straight to the start point, you can meet Gerard Rongen at 6.10 in front of the Doelen entrance, Willem Burger Zaal, Kruisplein 30. -
08:00 - 08:50Meet the experts 1-2-3
-
08:00 - 08:50Zaal 1Meet the expert 1 | Rational pharmacotherapy in children
-
08:00 - 08:50Zaal 9-10Meet the expert 2 | Optimal use of PK-PD in industry and academia (drug development and trials)
-
08:00 - 08:50Zaal 5-8Meet the expert 3 | The role of pharmacists in pharmacovigilance of patients participating in drug trials
-
-
08:00 - 14:00Willem Burger HalRegistration
-
09:00 - 10:10Zaal 1Plenary Session 3 | A vision for clinical evidence in Europe
-
09:00 - 09:30“A vision for clinical evidence in Europe”, slightly broadening the scope beyond clinical trials to include clinical evidence and real world evidence (step 3)
-
09:30 - 10:00Zaal 1General Assembly
-
10:00 - 10:10Zaal 1Poster Pitches (step 3-4)
WHO Step: 3-4
Abstracts
10:00 - 10:0239 | Interest of pharmacogenetics in statin-associated muscle symptoms: reappraisal using meta-epidemiological approachBy: Arthur Gougeon
10:02 - 10:04125 | Neuropsychological assessment of elderly people after RSV vaccination: study protocolBy: Aikaterini Stravoravdi
10:04 - 10:06194 | PREDICTIONS OF IMATINIB PHARMACOKINETICS IN PREGNANT WOMEN BY PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLINGBy: Paola Mian
10:06 - 10:08138 | Population pharmacokinetics of benzathine penicillin G in pregnant Ethiopian women with syphilisBy: Eshetie Birru
10:08 - 10:10306 | Is the acceptance of pharmacist interventions from a specialized pharmacist working on the ward higher than from a non-specialized pharmacist?By: Sarah Wilkes
-
-
10:10 - 10:30FeestzaalCoffee Break and Poster Session
Step 4. Individualized therapy
Step 5. Prescribing
-
10:30 - 12:30Parallel Sessions 6-7-8
WHO Step: 3-4
-
10:30 - 12:00Zaal 5-8Parallel 6| Clinical trials
-
10:30 - 11:00Innovations in trial transparancy
-
11:00 - 12:30Zaal 5-8Parallel 6| Abstract Presentations11:00 - 11:15
By: Constant VINATIER
11:15 - 11:30By: Bikash Medhi
11:30 - 11:45By: Kari Tikkinen
11:45 - 12:00By: Gustavo Adolfo Centeno Soto
12:00 - 12:15By: Amos De Jong
12:15 - 12:30By: Anne (A.C.) Taams
-
-
10:30 - 12:30Zaal 1Parallel 7 | Adverse reactions
-
10:30 - 11:00Forecasting drug safety: translational research to understand adverse reactions and predict safety
-
11:00 - 12:30Zaal 1Parallel 7 | Abstract Presentations11:00 - 11:15
By: Victoria Aniyar
11:15 - 11:30By: Lucía Arellano
11:30 - 11:45By: Noortje van Herwaarden
11:45 - 12:00By: Judit Pich
12:00 - 12:15By: Renske Grupstra
12:15 - 12:30By: Eleftheria Vlachou
-
-
10:30 - 12:30Zaal 9-10Parallel 8 | Precision Pharmacology in children, ontogeny and TDM
sponsored by IUPHAR
-
10:30 - 11:00Neonatel clinical pharmacology: Ontogeny at its best
-
11:00 - 12:30Zaal 9-10Parallel 8 | Abstract Presentations11:00 - 11:15
By: Motoyasu Miura
11:15 - 11:30By: Paola Mian
11:30 - 11:45By: Kathalijne Bruens
12:00 - 12:15By: Amir Hossein Alizadeh Bahmani
12:15 - 12:30By: Swantje Völler
-
-
-
12:30 - 14:00FeestzaalLunch and Poster Session
Step 4. Individualized therapy
Step 5. Prescribing
-
13:00 - 13:45Zaal 9-10Lunchsymposium CBG
As an (academic) drug developer, you may face a wide range of challenges during the development process. Regulators offer different tools to support (academic) researchers and small and medium-sized enterprises (SMEs) during their drug development process from the lab to the patient.
During this lunch-session Dr. Marjon Pasmooij from the Dutch Medicines Evaluation Board (Head Science Department) and Dr. Ralf Herold from the European Medicines Agency (Head of workstream Regulatory Science and Academia) will tell you more about the interaction possibilities for academia and SMEs with regulators. Support tools include amongst others innovation task force meetings, simultaneous national scientific advice, national scientific advice, and scientific advice at the European Medicines Agency.
Advice can relate to the regulatory or scientific strategy for all sections of a future authorisation dossier: chemical pharmaceutical, pharmacological toxicological/pre-clinical, pharmacokinetic, clinical or pharmacovigilance. It can also cover the entire product cycle: from the pre-clinical research phase to post-marketing change proposals.
During this lunch session there will be ample time for questions and answers (Q&A).
-
13:00 - 13:45Zaal 1Lunchsymposium Roche
Target Mediated Drug Disposition (TMDD) of Small Molecules
Perspective from the pharmaceutical industry:
TMDD for small molecules is often overlooked and frequently only becomes apparent during clinical studies. Preclinical and clinical signs of TMDD for small molecules will be presented. The impact of TMDD on preclinical studies, points to consider and typical results will be elaborated.
Modeling considerations to reflect pharmacokinetic data of small molecules with TMDD are illustrated on the basis of PBPK modeling and pop PK models.
In first-in-human studies, it is suggested that the phenomenon of TMDD should be carefully considered as this could result in clinically significant non-linear PK resulting in supra-proportional increases in exposure. Considerations for single and multiple dose studies and dose escalation are mapped out and discussed.
The audience is invited to discuss this topic and to share their view.
-
13:00 - 13:45Target Mediated Drug Disposition (TMDD) of Small Molecules
Perspective from the pharmaceutical industry:
TMDD for small molecules is often overlooked and frequently only becomes apparent during clinical studies. Preclinical and clinical signs of TMDD for small molecules will be presented. The impact of TMDD on preclinical studies, points to consider and typical results will be elaborated.
Modeling considerations to reflect pharmacokinetic data of small molecules with TMDD are illustrated on the basis of PBPK modeling and pop PK models.
In first-in-human studies, it is suggested that the phenomenon of TMDD should be carefully considered as this could result in clinically significant non-linear PK resulting in supra-proportional increases in exposure. Considerations for single and multiple dose studies and dose escalation are mapped out and discussed.
The audience is invited to discuss this topic and to share their view.
-
-
14:00 - 16:00Parallel Sessions 9-10-11
WHO Step: 4-5
-
14:00 - 16:00Zaal 1Parallel 9 | Gender differences in drug prescribing
sponsored by the Swedish Society
-
14:00 - 14:20Sex or gender differences in drug utilization
-
14:20 - 14:40Sex or gender differences in adverse drug events
-
14:45 - 16:00Zaal 1Parallel 9 | Abstract Presentations14:45 - 15:00
By: Lucia Bellas
15:00 - 15:15By: Rim Patti
15:15 - 15:30By: Amanda Evelo
15:30 - 15:45By: ALVARO CADENAS MANCEÑIDO
15:45 - 16:00By: Feng Deng
-
-
14:00 - 16:00Zaal 5-8Parallel 10 | Methodological developments in drug trials
-
14:00 - 14:30Registry-based trials: effective, innovative trial designs in cardiovascular drug development
-
14:45 - 16:00Zaal 5-8Parallel Session 10 | Abstract Presentations14:45 - 15:00
By: Mayro J. Cortés Pestana
15:00 - 15:15By: Ruben Malmberg
15:15 - 15:30By: Arnaud De Clercq
15:30 - 15:45By: Borja Garcia
-
-
14:00 - 16:00Zaal 9-10Parallel 11 | Dose Individualization of Biologics to Improve Patient Outcome
a Joint ACCP-EACPT Symposium
-
14:00 - 14:20Opening & Clinical pharmacology considerations of biologics: Fundamentals and principles
-
14:25 - 14:45Model informed precision dosing of targeted therapies in oncology: challenges and opportunities in clinical practice
-
14:50 - 15:10Size descriptors and disease biomarkers for dose individualization of biologicals in adult and pediatric SCT: a prospective clinical trial to improve outcome
-
15:15 - 15:45Parallel 11 | Abstract Presentations
By: David Burger
By: Julia Stingl
-
-
-
16:00 - 16:30FeestzaalTea Break and Poster Session
Step 4. Individualized therapy
Step 5. Prescribing
-
16:30 - 17:30Zaal 1Plenary Session 4 | Debate: How to reduce NNT?
WHO Step: 3-4
-
16:30 - 16:45Case pro Pharmacogenetics
-
16:45 - 17:00Case pro Therapeutic drug monitoring
-
17:00 - 17:05Comments Munir Pirmohamed
-
17:05 - 17:10Comments David Burger
-
17:10 - 17:30Discussion
-
-
17:30 - 18:30Zaal 1Satelite 5 EACPT Council Meeting
-
19:30 - 23:30Congress Dinner at Stadshaven Brouwerij
Enjoy the Congress Dinner in a most prestigious location, the City Harbor Brewery Stadshaven Brouwerij
Meet your friends and colleagues in an authentic Rotterdam setting.
We have you covered for transportation; this is a worry-free event for you.
Shuttle Buses Doelen - Stadshaven Brouwerij 19.00 - 19.45.
Shuttle Buses Stadshaven Brouwerij - Doelen 22.30 - 00.00.
Tuesday 11 June 2024
-
07:30 - 08:30Early Morning Bootcamp
On Tuesday 11 June, we start the day with a powerful kick off! In one of the most beautiful parks of Rotterdam, the park near the Euromast. Join us for a forty minutes workout and be ready for your next day at the congress. ‘We are in this together!’
Time 07.30 – 08.30
Address Euromast, Parkhaven 20, 3016 GM Rotterdam
Bring your own water -
07:30 - 08:30Early Morning Yoga
With Morning Yoga, you will start your day in an energetic way. And you will notice the positive effect throughout the day. Join us for a 30 minutes yoga meditation on Tuesday morning 11 June. And enjoy the unique scenery of the most beautiful park of Rotterdam near the Euromast.
Time 07.30 – 08.30
Address Euromast, Parkhaven 20, 3016 GM Rotterdam
Bring your own water, towel and if possible your yoga mat -
08:00 - 08:50Meet the experts | 4-5-6
(steps 3-6)
-
08:00 - 08:50Zaal 9-10Meet the expert 4 | How to perform a health economic study
-
08:00 - 08:50Zaal 5-8Meet the expert 5 | How to make and review an IB
-
08:00 - 08:50Zaal 1Meet the expert 6 | How to prove causality in pharmacovigilance in early and late/post marketing research
-
-
08:00 - 13:00Willem Burger HalRegistration
-
09:00 - 10:10Zaal 1Plenary Session 5 | Access to health care & the Green Deal in drug therapy
-
09:00 - 09:30Drug shortage from a European perspective: causes and solutions
-
09:30 - 10:00How to reduce environmental impact of pharmaceuticals (Green Deal of EU)
-
10:00 - 10:10Zaal 1Poster Pitches (step 5-6)
Abstracts
10:00 - 10:0259 | Long-Term Antibody Responses to COVAXIN and COVISHIELD Vaccines in Rheumatoid Arthritis Patients and healthy control populationBy: Madhavi Eerike
10:02 - 10:0467 | “Doctor, is your patient at risk for prescribing errors?” Identifying eligible patients for in-hospital pharmacotherapeutic stewardship: A matched case-control studyBy: Rashudy Mahomedradja
10:04 - 10:06116 | A good start is half the battle: antibiotic IV line residuals in the intensive care unitBy: Dorian Vanneste
10:08 - 10:10212 | Disproportionality analysis of neurological adverse reactions to COVID-19 vaccines: insights from EudravigilanceBy: Arturo Gomez
-
-
10:10 - 10:30FeestzaalCoffee Break and Poster Session
Step 6. Monitoring outcome and compliance
-
10:30 - 12:30Parallel Sessions 12-13-14
WHO Step: 5
-
10:30 - 12:30Zaal 1Parallel 12 | Teaching Clinical Pharmacology
-
10:30 - 11:00Student Run Clinics in Pharmacotherapy Education
Student Run Clinics in Pharmacotherapy Education
International student run clinic project (Ellen v Leeuwen, Belgium and Jitka Rychlíčková ,Czech Republic)
Local student run clinic projects (Floor van Rosse, Rotterdam, Roya Atyki Groningen, Marleen Leiden, Mariëlle Hartjes, Amsterdam + some students) -
11:00 - 11:20AI and Education
-
11:20 - 11:40Planetary Health Education in Prescribing
-
11:30 - 12:30Zaal 1Parallel 12 | Abstract Presentations11:40 - 11:50
By: Stephane Mouly
11:50 - 12:00By: Katja Just
12:00 - 12:10By: Rozita Abdolrahimi Raeni
12:10 - 12:20By: Helen C. Gallagher
-
-
10:30 - 12:30Zaal 5-8Parallel 13 | Pharmaco-economics
-
10:30 - 11:00Pharmaco-economic outcomes of trials
-
10:45 - 12:30Zaal 5-8Parallel 13 | Abstract Presentations11:00 - 11:15
By: Christine Van Hattem
11:15 - 11:30By: Anne-Sophie Klein Gebbink
11:30 - 11:45By: Zohreh Safipour
11:45 - 12:00By: Caridad Pontes
12:00 - 12:15By: Agda Van Huët
-
-
10:30 - 12:30Zaal 9-10Parallel 14 | Implementation of guidelines
-
10:30 - 11:00Implementation of Pharmacogenetic guidelines
-
11:00 - 12:30Zaal 9-10Parallel 14 | Abstract Presentations11:00 - 11:15
By: Amal Zoubi
11:15 - 11:30By: Leonie Bogaard
11:30 - 11:45By: Jacqueline Hugtenburg
11:45 - 12:00By: David Ramírez Saco
12:00 - 12:15By: Santosh Kumar
12:15 - 12:30By: Igor Rubinić
-
-
-
12:30 - 14:00FeestzaalLunch and Poster Session
Step 6. Monitoring outcome and compliance
-
13:00 - 13:45Zaal 1Lunchsymposium ICON
-
13:00 - 13:15Departing from guidance: Dose selection in clinic pharmacology studies investigating intrinsic and extrinsic effects on PK and safety
Rüdiger Kaspera, Director Clinical Pharmacology, ICON
-
13:15 - 13:30How protein binding data from studies in hepatically or renally impaired patients contribute to dosing recommendations
Gerhard Arold, Senior Director Scientific Affairs, Clinical Pharmacology, ICON
-
13:30 - 13:45Expediting clinical pharmacology studies in 2024; pilot inventory of critical elements
Dirk Cerneus, Senior Director, Clinical Pharmacology, ICON
-
-
14:00 - 16:00Parallel Sessions 15-16-17
WHO Step: 6
-
14:00 - 16:00Zaal 5-8Parallel 15 | Late breaking research in Clincial Pharmacology
-
14:00 - 16:00Zaal 5-8Parallel 15 | Abstract Presentations14:00 - 14:15
By: Nurgul Aldiyarova
14:15 - 14:30By: Ellen Van Leeuwen
14:30 - 14:45By: Ophir Lavon
14:45 - 15:00By: Emma SAINT-CARLIER
15:00 - 15:15By: Jean-Christophe LEGA
15:15 - 15:30By: Jitka Rychlickova
-
-
14:00 - 16:00Zaal 9-10Parallel 16 | TDM in personalized pharmacotherapy
-
14:00 - 14:30Precision therapy in organ transplant patients - the use of TDM and AI
-
14:30 - 15:00Innovative monitoring of drug effects, TDM and safety
-
15:00 - 16:00Parallel 16 | Abstract Presentations15:00 - 15:15
By: Zhiyuan Tan
15:15 - 15:30By: Josephine Kranendonk
15:30 - 15:45By: Hanieh Abedian Kalkhoran
15:45 - 16:00By: Adomas Danilevicius
-
-
14:00 - 16:00Zaal 1Parallel 17 | Pharmacovigilance in the elderly
-
14:00 - 14:30Adverse events and pharmacovigilance in the elderly
-
14:30 - 16:00Zaal 1Parallel 17 | Abstract Presentations14:30 - 14:45
By: Naldy Parodi López
14:45 - 15:00By: Arnaud De Clercq
15:00 - 15:15By: Ekaterina Ilyina
15:15 - 15:30By: Petra Spies
15:30 - 15:45By: Eline Engelen
15:30 - 15:45By: Massimo Magliocca
-
-
-
16:00 - 16:30FeestzaalTea Break and Poster Session
Step 6. Monitoring outcome and compliance
-
16:30 - 17:30Zaal 1Award lectures and Closing Ceremony
-
16:30 - 16:50Announcement of Scientific Award winner and presentation by the laureate
-
16:50 - 17:00Announcement of the three Poster Award winners
-
17:00 - 17:10Photo session of all laurates I Life Time Achievement Award, Scientific Award, EPHAR-EACPT translational research awards (Pharmacology and Clinical Pharmacology), Poster Awards
-
17:10 - 17:20Closing and announcement of Helsinki meeting
-